Shamburg News · 8-K filed Nov 12, 2026, 4:05 PM EST
Candel Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Update
CADL · Candel Therapeutics, Inc.
- Earnings
- Materiality: high
Candel Therapeutics reported a net loss of $21.9 million for the quarter ended September 30, 2026, compared with a net loss of $11.3 million for the third quarter of 2025, with basic and diluted loss per share of $0.28. Research and development expenses were $15.6 million and general and administrative expenses were $7.4 million. The company reported cash and cash equivalents of $203.1 million as of September 30, 2026, and expects them to fund operations into Q2 2028, and it now plans to submit a BLA for aglatimagene in prostate cancer in mid-2027.
Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193125-26-458316.
Written from the filing by Shamburg Markets. Figures are as reported by the company.